The field of cancer genetics is at an exciting juncture in which the tools for interrogating cancer genes, genomes and networks have progressed enormously. The overall goal of the Cancer Genomes and Networks program (CGN) is to create a fertile environment for research on genetic abnormalities causing, or consistently associating with, the induction and progression of neoplasia and its systemic effects, and then to apply insights from these studies to clinical and translational research and patient treatment. The program is organized into four themes: Cancer genomes and genome integrity. Cancer epigenomes and transcriptional networks, Cancer proteomes and protein signaling networks, and Cancer metabolomes and metabolic networks. The CGN program has 31 members from 11 academic departments with $18.5 Million of peer reviewed research grant funding (annual direct costs). Members of the CGN program published 814 programmatically aligned articles since 2007, 10% were the result of intra-programmatic collaborations, 14% were inter-programmatic. The Cancer Center adds value to CGN by providing shared resource facilities, human tissue samples, and pilot project grants for translational research. The CGN program adds value to the Cancer Center by developing new methods/ technologies for high throughput analyses of complex biological systems that in the long run will benefit the diagnosis and the treatment of cancer.
There is growing optimism that knowledge of the genetic make-up of individual tumors will allow both a greater understanding of the development of cancer and more successful individualized treatment of cancer. The CGN program will contribute to this goal through its focus on state-of-the-art genetics and genomics methods and their application to cancer research and treatment
| Dow, Michelle; Pyke, Rachel M; Tsui, Brian Y et al. (2018) Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115:E9879-E9888 |
| Que, Xuchu; Hung, Ming-Yow; Yeang, Calvin et al. (2018) Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature 558:301-306 |
| Murzin, Vyacheslav L; Woods, Kaley; Moiseenko, Vitali et al. (2018) 4? plan optimization for cortical-sparing brain radiotherapy. Radiother Oncol 127:128-135 |
| Norton, Jeffrey A; Kim, Teresa; Kim, Joseph et al. (2018) SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg 22:32-42 |
| Ikeda, Sadakatsu; Tsigelny, Igor F; Skjevik, Åge A et al. (2018) Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma. Oncologist 23:586-593 |
| Buckley, Alexandra R; Ideker, Trey; Carter, Hannah et al. (2018) Exome-wide analysis of bi-allelic alterations identifies a Lynch phenotype in The Cancer Genome Atlas. Genome Med 10:69 |
| Parish, Austin J; Nguyen, Vi; Goodman, Aaron M et al. (2018) GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers. Cancer 124:4080-4089 |
| Xu, Selene; Thompson, Wesley; Ancoli-Israel, Sonia et al. (2018) Cognition, quality-of-life, and symptom clusters in breast cancer: Using Bayesian networks to elucidate complex relationships. Psychooncology 27:802-809 |
| Tao, Li; Schwab, Richard B; San Miguel, Yazmin et al. (2018) Breast Cancer Mortality in Older and Younger Breast Cancer Patients in California. Cancer Epidemiol Biomarkers Prev : |
| Sagredo, Eduardo A; Blanco, Alejandro; Sagredo, Alfredo I et al. (2018) ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biol Res 51:36 |
Showing the most recent 10 out of 862 publications
